Advances in genetic testing, enable the identification of genetic causes even before symptoms appear, allowing for timely ...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), January 29, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the ...

GENFIT signs royalty financing deal with HealthCare Royalty (HCRx) providing up to €185 million non-dilutive capital: €130 million upfront, ...

April 24, 2025 Publication of Full Year 2024 financial statements The 2024 Universal Registration Document and Annual Financial Report (included in the Universal Registration Document), as well ...

Advances in science and technology have allowed researchers to gain a better understanding of the pathophysiology leading to long-term neurologic damage in newborns. Intrapartum events are now ...

€130 million upfront, with eligibility to receive up to €55 million in two additional instalments based on near-term milestones Closing subject to approval by the 2025 OCEANE bondholders at upcoming ...